Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Local Advanced or Metastatic Non-Small Cell Lung Cancer
Latest Information Update: 31 Mar 2023
At a glance
- Drugs Osimertinib (Primary) ; Bevacizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Mar 2023 Planned End Date changed from 31 Jul 2024 to 31 Dec 2024.
- 27 Mar 2023 Planned primary completion date changed from 31 Jul 2023 to 31 Jul 2024.
- 27 Jul 2021 New trial record